SG11201707683YA - C/ebp alpha sarna compositions and methods of use - Google Patents
C/ebp alpha sarna compositions and methods of useInfo
- Publication number
- SG11201707683YA SG11201707683YA SG11201707683YA SG11201707683YA SG11201707683YA SG 11201707683Y A SG11201707683Y A SG 11201707683YA SG 11201707683Y A SG11201707683Y A SG 11201707683YA SG 11201707683Y A SG11201707683Y A SG 11201707683YA SG 11201707683Y A SG11201707683Y A SG 11201707683YA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- ebp alpha
- sarna compositions
- compositions
- alpha sarna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562150889P | 2015-04-22 | 2015-04-22 | |
| US201562235778P | 2015-10-01 | 2015-10-01 | |
| US201662308521P | 2016-03-15 | 2016-03-15 | |
| PCT/GB2016/051117 WO2016170349A1 (en) | 2015-04-22 | 2016-04-21 | C/ebp alpha sarna compositions and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201707683YA true SG11201707683YA (en) | 2017-11-29 |
Family
ID=55948895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201707683YA SG11201707683YA (en) | 2015-04-22 | 2016-04-21 | C/ebp alpha sarna compositions and methods of use |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10912790B2 (enExample) |
| EP (1) | EP3286316A1 (enExample) |
| JP (4) | JP6768701B2 (enExample) |
| KR (2) | KR102760315B1 (enExample) |
| CN (2) | CN108291228A (enExample) |
| AU (3) | AU2016251415B9 (enExample) |
| CA (1) | CA2980975A1 (enExample) |
| SG (1) | SG11201707683YA (enExample) |
| WO (1) | WO2016170349A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102507624B1 (ko) * | 2013-11-22 | 2023-03-09 | 미나 테라퓨틱스 리미티드 | C/ebp 알파 짧은 활성화 rna 조성물 및 사용 방법 |
| WO2018104538A1 (en) * | 2016-12-08 | 2018-06-14 | Curevac Ag | Rna for treatment or prophylaxis of a liver disease |
| AU2018330495A1 (en) | 2017-09-08 | 2020-03-26 | Mina Therapeutics Limited | Stabilized hnf4a sarna compositions and methods of use |
| EP3679140B1 (en) * | 2017-09-08 | 2022-11-16 | MiNA Therapeutics Limited | Stabilized cebpa sarna compositions and methods of use |
| CN108103108A (zh) * | 2018-01-30 | 2018-06-01 | 上海交通大学医学院附属瑞金医院 | Cebpa基因缺失斑马鱼突变体的制备及其应用 |
| EP3752165A1 (en) | 2018-02-16 | 2020-12-23 | Mina Therapeutics Limited | C/ebp alpha sarna compositions and methods of use |
| CN110959042B (zh) * | 2018-04-10 | 2022-10-18 | 中美瑞康核酸技术(南通)研究院有限公司 | 一种新型小激活rna |
| CA3102334A1 (en) * | 2018-06-15 | 2019-12-19 | Mina Therapeutics Limited | Combination therapies comprising c/ebp alpha sarna |
| EP4003423A4 (en) * | 2019-07-26 | 2024-03-06 | MiNA Therapeutics Limited | Compositions and methods of using c/ebp alpha sarna |
| EP4003060A4 (en) * | 2019-07-29 | 2023-08-02 | Brightseed, Inc. | Method for improving digestive health |
| CN114585738A (zh) * | 2019-09-20 | 2022-06-03 | 中美瑞康核酸技术(南通)研究院有限公司 | 用于治疗血小板减少症的核酸分子及其应用 |
| EP4069848A4 (en) * | 2019-12-03 | 2024-02-28 | Merck Sharp & Dohme LLC | IN VITRO CELL-BASED POWER DOSING |
| GB202019692D0 (en) * | 2020-12-14 | 2021-01-27 | Apterna Ltd | Aptamer-sirna fusions |
| GB2618000A (en) | 2020-12-28 | 2023-10-25 | T Gjerde Douglas | Temperature stable nucleic acid method for preparing vaccine |
| US20240301409A1 (en) * | 2021-02-07 | 2024-09-12 | Ractigen Therapeutics | Chemically Modified Small Activating RNA |
| US20240207304A1 (en) | 2021-04-28 | 2024-06-27 | Mina Therapeutics Limited | Combination Therapies Comprising C/EBP Alpha saRNA |
| KR102428121B1 (ko) * | 2021-10-20 | 2022-08-08 | 주식회사 네오나 | 변형된 rt-let7을 유효성분으로 포함하는 간암의 예방 또는 치료를 위한 딜리버리 시스템 |
| CN114306367B (zh) * | 2021-08-27 | 2023-03-28 | 赵小洋 | 一种含有C/EBPα-saRNA的组合物 |
| WO2024129571A1 (en) * | 2022-12-12 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Treatment of type 2 diabetes and/or chronic kidney disease with hepatocyte nuclear factor 4 alpha (hnf4a) agonists |
| WO2024134199A1 (en) * | 2022-12-22 | 2024-06-27 | Mina Therapeutics Limited | Chemically modified sarna compositions and methods of use |
| WO2024165876A2 (en) * | 2023-02-10 | 2024-08-15 | Mina Therapeutics Limited | Compositions and methods of using c/ebp alpha sarna |
| WO2024175887A1 (en) | 2023-02-22 | 2024-08-29 | Mina Therapeutics Limited | Compositions and methods of using c/ebp alpha sarna |
| KR20240138691A (ko) * | 2023-03-13 | 2024-09-20 | 부산대학교 산학협력단 | 류마티스 관절염 진단용 바이오마커 조성물, 이를 이용한 진단용 키트 및 이를 이용한 류마티스 관절염 진단방법 |
| WO2025007024A1 (en) * | 2023-06-29 | 2025-01-02 | Repertoire Immune Medicines, Inc. | Lipid particles for delivering a payload |
| WO2025052098A1 (en) | 2023-09-08 | 2025-03-13 | Mina Therapeutics Limited | Tmem173 sarna compositions and methods of use |
| CN118480552B (zh) * | 2024-01-18 | 2024-10-01 | 成都先衍生物技术有限公司 | 一种靶向CEBPA基因表达的saRNA及其用途 |
| WO2025224036A1 (en) * | 2024-04-22 | 2025-10-30 | Mina Therapeutics Limited | Chemically modified sarna compositions and methods of use |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2990410A1 (en) * | 2004-08-10 | 2016-03-02 | Alnylam Pharmaceuticals Inc. | Chemically modified oligonucleotides |
| CA2743074A1 (en) * | 2008-11-13 | 2010-05-20 | Erasmus University Medical Center Rotterdam | Efficient detection of double mutants of the cebpa gene in aml. |
| ES2629339T3 (es) * | 2009-06-16 | 2017-08-08 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la paraoxonasa 1 (pon1) por inhibición de transcrito antisentido natural a pon1 |
| GB201010557D0 (en) * | 2010-06-23 | 2010-08-11 | Mina Therapeutics Ltd | RNA molecules and uses thereof |
| DK2638163T3 (en) * | 2010-11-12 | 2017-07-24 | Massachusetts Gen Hospital | POLYCOMB-ASSOCIATED NON-CODING RNAs |
| EP3456828B1 (en) * | 2011-06-21 | 2022-04-27 | MiNA Therapeutics Limited | Albumin production and cell proliferation |
| DE102011079572B4 (de) * | 2011-07-21 | 2024-12-05 | Endress+Hauser Conducta Gmbh+Co. Kg | Gradiometer zur Bestimmung der elektrischen Leitfähigkeit eines in einem Behältnis enthaltenen Mediums |
| HK1214628A1 (zh) * | 2012-11-05 | 2016-07-29 | Pronai Therapeutics, Inc. | 寡核苷酸癌症療法的給藥和施用 |
| KR20150087270A (ko) * | 2012-11-05 | 2015-07-29 | 프로나이 테라퓨틱스, 인코포레이티드 | Bcl2 발현 조절에 의한 암치료용 바이오마커 이용 방법 |
| WO2014078468A2 (en) * | 2012-11-15 | 2014-05-22 | Bristol-Myers Squibb Company | Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent |
| KR102507624B1 (ko) * | 2013-11-22 | 2023-03-09 | 미나 테라퓨틱스 리미티드 | C/ebp 알파 짧은 활성화 rna 조성물 및 사용 방법 |
| CN114224907A (zh) | 2015-07-02 | 2022-03-25 | 希望之城 | 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法 |
-
2016
- 2016-04-21 US US15/568,139 patent/US10912790B2/en active Active
- 2016-04-21 KR KR1020237037891A patent/KR102760315B1/ko active Active
- 2016-04-21 EP EP16721209.1A patent/EP3286316A1/en active Pending
- 2016-04-21 SG SG11201707683YA patent/SG11201707683YA/en unknown
- 2016-04-21 WO PCT/GB2016/051117 patent/WO2016170349A1/en not_active Ceased
- 2016-04-21 CA CA2980975A patent/CA2980975A1/en active Pending
- 2016-04-21 CN CN201680034224.1A patent/CN108291228A/zh active Pending
- 2016-04-21 CN CN202210140475.5A patent/CN114525279A/zh active Pending
- 2016-04-21 KR KR1020177030397A patent/KR102599712B1/ko active Active
- 2016-04-21 AU AU2016251415A patent/AU2016251415B9/en active Active
- 2016-04-21 JP JP2017554886A patent/JP6768701B2/ja active Active
-
2019
- 2019-07-31 AU AU2019210578A patent/AU2019210578B2/en active Active
-
2020
- 2020-09-23 JP JP2020158141A patent/JP6931733B2/ja active Active
- 2020-12-09 US US17/117,025 patent/US20210187007A1/en not_active Abandoned
-
2021
- 2021-08-16 JP JP2021132267A patent/JP2021192616A/ja active Pending
-
2022
- 2022-04-08 AU AU2022202355A patent/AU2022202355A1/en not_active Abandoned
-
2024
- 2024-03-13 JP JP2024038710A patent/JP2024079713A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024079713A (ja) | 2024-06-11 |
| KR102760315B1 (ko) | 2025-02-04 |
| CA2980975A1 (en) | 2016-10-27 |
| AU2016251415B2 (en) | 2019-05-02 |
| CN114525279A (zh) | 2022-05-24 |
| US20200376020A1 (en) | 2020-12-03 |
| US10912790B2 (en) | 2021-02-09 |
| JP2021192616A (ja) | 2021-12-23 |
| KR20230156961A (ko) | 2023-11-15 |
| EP3286316A1 (en) | 2018-02-28 |
| JP2018516545A (ja) | 2018-06-28 |
| AU2022202355A1 (en) | 2022-04-28 |
| KR20170136542A (ko) | 2017-12-11 |
| JP6768701B2 (ja) | 2020-10-14 |
| US20210187007A1 (en) | 2021-06-24 |
| AU2019210578A1 (en) | 2019-08-22 |
| AU2019210578B2 (en) | 2022-01-13 |
| AU2016251415B9 (en) | 2019-05-23 |
| WO2016170349A1 (en) | 2016-10-27 |
| JP2021000119A (ja) | 2021-01-07 |
| CN108291228A (zh) | 2018-07-17 |
| JP6931733B2 (ja) | 2021-09-08 |
| AU2016251415A1 (en) | 2017-10-12 |
| KR102599712B1 (ko) | 2023-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201707683YA (en) | C/ebp alpha sarna compositions and methods of use | |
| IL274276A (en) | CASZ preparations and methods of use | |
| GB2582100B (en) | CAS12C Compositions and methods of use | |
| ZA201707981B (en) | Compositions of obeticholic acid and methods of use | |
| ZA201801511B (en) | Flavonoid compositions and methods of use | |
| IL257307B (en) | Transgenic crispr–cas9 preparations and methods of use | |
| HUE056172T2 (hu) | Szelenoorganikus vegyületeket tartalmazó készítmények és eljárások alkalmazásukra | |
| PL3277270T3 (pl) | Kompozycje i sposoby leczenia niedokrwistości | |
| HUE068774T2 (hu) | Magas elaszticitású hialuronán készítmények és azok alkalmazásai | |
| ZA202104969B (en) | Compositions comprising 15-hepe and methods of using the same | |
| ZA201906169B (en) | Synthekine compositions and methods of use | |
| PL3349743T3 (pl) | Sposoby i kompozycje do hamowania oddziaływania dcn1-ubc12 | |
| PT3288379T (pt) | Composições de péptido e métodos de utilização | |
| EP3190886A4 (en) | Compositions and methods of use thereof | |
| IL265761A (en) | Terlipressin compounds and methods of using them | |
| IL256843B (en) | Cleaning products and methods of using them | |
| GB2600888B (en) | Magnesium biotinate compositions and methods of use | |
| SG11201803284YA (en) | Novel method of use and compositions | |
| GB201511799D0 (en) | Composition and methods of treatment | |
| IL246711A0 (en) | Biologically active haloperoxidase compositions and methods of using them | |
| EP3253396A4 (en) | Probiotic compositions and methods of use | |
| EP3207029A4 (en) | Tryptamide compositions and methods of use | |
| IL261794A (en) | Preparations and methods for using them | |
| IL247645A0 (en) | Preparations of seleno-organic compounds and methods of using them | |
| ZA201606358B (en) | Compositions of selenoorganic compounds and methods and methods of use thereof |